Blog

Misty Dawn Shields: Groundbreaking study challenging the dogma of ‘YAP1’ neuroendocrine subtype in SCLC

Photo taken from aacrjournals.org

May 12, 2024, 03:12

Misty Dawn Shields: Groundbreaking study challenging the dogma of ‘YAP1’ neuroendocrine subtype in SCLC

Misty Dawn Shields, Assistant Professor of Clinical Medicine, Division of Hematology/Oncology at IU School of Medicine, shared a post by Jarushka Naidoo on X:

“Groundbreaking study by Sutherland Lab and colleagues challenging the dogma of ‘YAP1’ neuroendocrine subtype in SCLC. This research finally clarifies how YAP1+ actually appears in SMARCA4-deficient undifferentiated thoracic tumors, not in SCLC. ”

Quoting Jarushka Naidoo‘s post:

“Interesting multi-omic analysis of previously classified SCLC cell lines (YAP1+), identifies that these tumors represent diseases that ‘mimic’ SCLC- in this case- SMARCA4-deficient thoracic tumors, that have a poor prognosis.”

Source: Misty Dawn Shields/X and Jarushka Naidoo/X

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials. She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.